43 research talents awarded scholarships to help secure Denmark's future
43 of Denmark's most talented students in the biotechnological and pharmaceutical sciences will today be awarded Novo Scholarships, the largest of their kind in Denmark. "We must learn how to nurture the wealth of research talent to be found in Denmark. The Novo Scholarships are a good example of this and can inspire more young people to become interested in the natural sciences," says Morten Østergaard, Danish Minister for Research, Innovation and Higher Education. 
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Signifor® (SOM230, pasireotide) for the treatment of Cushing's disease. There are currently no approved medicines in the European Union (EU) targeting Cushing's disease, a debilitating endocrine disorder caused by excess cortisol in the body due to the presence of a non-cancerous pituitary tumor[1],[2]. 
Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that the European Medicines Agency (EMA) has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme® (agalsidase beta). "This approval by the EMA represents an important milestone in our manufacturing recovery and path toward unconstrained supply for all patients," said Genzyme's President and CEO David Meeker. 
AstraZeneca has entered into a three-year collaboration agreement with IMS Health, the leading provider of information, services and technology for the healthcare sector, to advance the use of real-world evidence based on observational and retrospective studies throughout Europe to inform the delivery of effective and cost-efficient healthcare. The partnership with IMS Health will give AstraZeneca access to pre-existing anonymised electronic health records, which include clinical outcome, economic and treatment pattern data. 
GlaxoSmithKline (GSK) has announced the launch of MyAsthma, the UK's first, free personalised health application (app) designed to help people over the age of 12 take greater control of their asthma. The app features the Asthma Control Test™ (ACT), a simple 30-second test developed by leading asthma experts, which gives asthma patients a useful measure of their asthma control in an easy-to-understand score. 
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced the acceptance for review of their once-daily ADHD medicinal product VENVANSE® (lisdexamfetamine dimesylate) by the Medicines Healthcare products Regulatory Agency (MHRA), UK. The MHRA have agreed to act as the Reference Member State for this Decentralised Procedure (DCP) which will initially include eight European countries. 
Bayer HealthCare has submitted an application for marketing authorization to the European Medicines Agency (EMA) for the oral anticoagulant Xarelto® (rivaroxaban) in combination with standard antiplatelet therapy for secondary prevention after an Acute Coronary Syndrome (ACS). Rivaroxaban is an oral direct Factor Xa inhibitor being jointly developed by Bayer HealthCare and Janssen Research & Development, L.L.C. Rivaroxaban is the only new oral anticoagulant that has been submitted for use in this indication.